SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the medical
care team at Hong Kong Sanatorium & Hospital (HKSH) in
Hong Kong treated the first cancer
patient in Asia using the
Radixact® System, the next-generation
TomoTherapy® platform, with ClearRT™ helical
fan-beam kVCT imaging. With the installation of ClearRT the team
has raised the bar for other hospitals using radiation therapy as
an option in cancer care. The integrated helical imaging and
radiation delivery system will enable the HKSH team to generate
clear, high-fidelity images that improve their ability to see the
tumor and adjacent healthy tissue, and will make it easier to
provide more targeted treatments to more patients each day.
The HKSH medical care team was the first in Asia to treat patients with the Accuray
proprietary Synchrony® technology on both the
CyberKnife® M6™ and Radixact Systems and is now the
first to use ClearRT with Radixact, which supports their commitment
to providing excellence in cancer care using the most advanced
technology available. The ability to significantly improve clarity
in imaging was especially important to the team when treating their
first patient, a 35 year-old man diagnosed with tongue cancer.
The treatment region included the oral cavity and neck lymph nodes,
so minimizing dose to nearby critical organs was crucial. ClearRT
improved soft-tissue visualization, enabling the HKSH team to
deliver a highly accurate and precise treatment.
"The HKSH team is excited to expand on the Radixact System's
capabilities with the addition of the ClearRT imaging technology.
The ClearRT imaging modality provides enhanced image quality and
better soft-tissue visualization. With this new feature, the
scanning time was reduced by 77% for this case. The registration
time required was also significantly shortened. The patient
throughput can be increased with abbreviated treatment time, so
more patients can benefit from this precise and advanced
technology," said Dr. Daniel Chua, Associate Director of Department of
Radiotherapy.
ClearRT is a novel, helical CT imaging solution that, when
integrated with Synchrony Real-time Motion Synchronization and
Adaptive Treatment Delivery Technology, on the Radixact System
provides a powerful tool that enable medical care teams to
deliver extremely accurate and precise ultra-hypofractionated
treatments, especially to tumors that move during treatment.
ClearRT helical kVCT images can be used within the Accuray
PreciseART® automated dose trending tool for clinicians
to evaluate if plan adaptation would be beneficial, enabling the
most personalized patient care.
"Accuray is honored to have the opportunity to further our
long-standing partnership with the HKSH team. They are forward
thinking and put a priority on investing in innovative technology
that will help them to provide more effective outcomes for their
cancer patients," said Suzanne
Winter, President of Accuray. "ClearRT on the Radixact
System represents an evolution of the TomoTherapy platform that we
believe will lead to meaningful improvements in the treatment of
cancer for clinicians and their patients and increase the range of
patients and tumors that can be treated."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to the anticipated benefits of
ClearRT to clinicians and patients, the potential for ClearRT to
lead to meaningful improvements in the treatment of cancer,
clinical applications, clinical results, patient experiences and
patient outcomes. These forward-looking statements involve risks
and uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product innovations and releases; the
company's ability to develop new products or improve existing
products to meet customers' needs; the company's ability to
anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on April
30, 2021, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Accuray
Beth Kaplan
+1 (408) 789-4426
bkaplan@accuray.com
Christy Maginn
Havas
+1 (703) 297-7194
christina.maginn@havas.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hong-kong-sanatorium--hospital-transforms-cancer-care-in-asia-with-treatment-of-first-patient-using-the-accuray-radixact-system-and-clearrt-helical-fan-beam-kvct-imaging-301338849.html
SOURCE Accuray Incorporated